Purchase Short-Term Access

Review: Oral drugs for type 2 diabetes, alone or in combination, have different relative benefits and harms for surrogate endpoints
Juan Pablo Domecq, MD; Gabriela Prutsky, MD; Victor M. Montori, MD

Annals of Internal Medicine 2011;155:JC2-4. doi:10.7326/0003-4819-155-4-201108160-02004

Purchase Online access to this article for 24 hours
Buy Now for $32.00
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.